Search

Your search keyword '"Lastoria, Secondo"' showing total 177 results
Start Over Author "Lastoria, Secondo" Search Limiters Full Text
177 results on '"Lastoria, Secondo"'

1. Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization

Author

Mallardo, Domenico, Simeone, Ester, Vanella, Vito, Vitale, Maria Grazia, Palla, Marco, Scarpato, Luigi, Paone, Miriam, De Cristofaro, Teresa, Borzillo, Valentina, Cortellini, Alessio, Sparano, Francesca, Pignata, Sandro, Fiore, Francesco, Caracò, Corrado, Maiolino, Piera, Petrillo, Antonella, Cavalcanti, Ernesta, Lastoria, Secondo, Muto, Paolo, Budillon, Alfredo, Warren, Sarah, and Ascierto, Paolo Antonio

Published
2022
Full Text
View/download PDF

2. Sentinel Lymph Node Biopsy (SLNB) for Early-Stage Head and Neck Squamous-Cell Carcinoma of the Tongue: Twenty Years of Experience at I.N.T. “G.Pascale”

Author

Ionna, Franco, primary, Pavone, Ettore, additional, Aversa, Corrado, additional, Maffia, Francesco, additional, Spinelli, Raffaele, additional, Carraturo, Emanuele, additional, Salzano, Giovanni, additional, Maglitto, Fabio, additional, Sarcinella, Marco, additional, Fusco, Roberta, additional, Granata, Vincenza, additional, Lastoria, Secondo, additional, Del Prato, Francesco, additional, and Maglione, Maria Grazia, additional

Published
2024
Full Text
View/download PDF

6. Response to Peptide Receptor Radionuclide Therapy in Pheocromocytomas and Paragangliomas: A Systematic Review and Meta-Analysis

Author

Marretta, Antonella Lucia, primary, Ottaiano, Alessandro, additional, Iervolino, Domenico, additional, Bracigliano, Alessandra, additional, Clemente, Ottavia, additional, Di Gennaro, Francesca, additional, Tafuto, Roberto, additional, Santorsola, Mariachiara, additional, Lastoria, Secondo, additional, and Tafuto, Salvatore, additional

Published
2023
Full Text
View/download PDF

7. Electrochemotherapy in pancreatic adenocarcinoma treatment: pre-clinical and clinical studies

Author

Bimonte Sabrina, Leongito Maddalena, Granata Vincenza, Barbieri Antonio, Vecchio Vitale del, Falco Michela, Nasto Aurelio, Albino Vittorio, Piccirillo Mauro, Palaia Raffaele, Amore Alfonso, Giacomo Raimondo di, Lastoria Secondo, Setola Sergio Venanzio, Fusco Roberta, Petrillo Antonella, and Izzo Francesco

Subjects
electrochemotherapy, pancreatic carcinoma, bleomycin, pre-clinical study, clinical study, safety, efficacy, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

Pancreatic adenocarcinoma is currently one of the deadliest cancers with high mortality rate. This disease leads to an aggressive local invasion and early metastases, and is poorly responsive to treatment with chemotherapy or chemo-radiotherapy. Radical resection is still the only curative treatment for pancreatic cancer, but it is generally accepted that a multimodality strategy is necessary for its management. Therefore, new alternative therapies have been considered for local treatment.

Published
2016
Full Text
View/download PDF

9. Comparison of [68Ga]Ga-PSMA-11, [18F]PSMA1007 and [177Lu]Lu-PSMA-617 in detecting the same prostate cancer lesions. The evidences from the clinical practice in a dedicated Cancer Institution

Author

de Marino, Roberta, Morisco, Anna, Maisto, Costantina, Di Gennaro, Francesca, Rossi, Alfredo, Carideo, Luciano, Raddi, Marco, Rossetti, Sabrina, Maiolino, Piera, Pignata, Sandro, and Lastoria, Secondo

Subjects
PCa, mCRPC, [68Ga]Ga-PSMA-11, [18F]PSMA-1007, SUVmax, [177Lu]Lu-PSMA-617, RLT, PSA
Abstract

Background. PET/CT with radiolabeled PSMA inhibitors gained clinical relevance in the imaging and therapy of mCRPC patients. Different PSMA radioligands are currently available for PET imaging but few data exist on comparative rate of detection, degree of uptake, correlation with RLT effectiveness, levels of PSA and disease symptoms. Methods. Fifteen mCRPC patients underwent to [68Ga]Ga-PSMA-11/[18F]PSMA-1007 PET/CT imaging, and to 4 up to 6 [177Lu]Lu-PSMA-617 RLT cycles (n. 6). The detection rate and the uptake in target lesions or in normal organs were compared to highlight similarities and differences. Results. [68Ga]/[18F]-PSMA-radioligands show similar rates of detection with overlapping levels of uptake in PCa sites, that is different in normal organs. In the six patients who completed RLT, [177Lu]Lu-PSMA-617 targeted the same lesions causing a drastic reduction in SUVmax after the second dose. Conclusions. These three PSMA radioligands concentrated in the same foci of PCa disease. Thus, the choice for PET imaging may be defined adopting the following parameters: local availability, costs of production/purchasing, number of studies and clinical demands for PET/CT per session. The use of PET radioligands did not influence a proper selection of patients to treat by RLT.

Published
2023
Full Text
View/download PDF

10. A comparison of simplified protocols of personalized dosimetry in NEN patients treated by Radio Ligand Therapy (RLT) with [177Lu]Lu-DOTATATE to favour its use in clinical practice

Author

Pirozzi Palmese, Valentina, D'Ambrosio, Laura, Di Gennaro, Francesca, Maisto, Costantina, de Marino, Roberta, Morisco, Anna, Coluccia, Sergio, Di Gennaro, Pierluigi, De Lauro, Francesco, Raddi, Marco, Gaballo, Paolo, Tafuto, Salvatore, Celentano, Egidio, and Lastoria, Secondo

Subjects
RLT, neuroendocrine neoplasms, dosimetry, absorbed dose, 177Lu
Abstract

The role of internal dosimetry is usually proposed for investigational purposes in patients treated by RLT; while the application in clinical practice is still very restricted. The limited application is partially justified by the use of fixed doses, the lack of well established methods to calculate absorbed doses to organ at risk and tumours, the time consuming needed for imaging and calculations, the lack of trained, highly-specialized personal, and the discomfort to the patients for the numerous and prolonged sessions of imaging. Methods: In our series thirty patients with NENs, candidate to RLT with Lutathera®, dosimetry was performed after each of the four cycles and used as reference method (M0). Data were then used to assess the feasibility of simplified, lighter, protocols: defining the dosimetry after the first cycle only (M1) and after the first and last cycles (M2). Results: The mean difference, comparing the cumulative absorbed dose (cAD) obtained with M1 and M0, was: -10% for kidneys, -5% for spleen, +34% for liver, +13% for red marrow and +37% for tumour lesions. Such differences decreased comparing cAD obtained with M2 and M0: -3% for kidneys, -0,3% for spleen, +6% for liver, +3% for red marrow and 6% for tumour lesions. Conclusions: The dosimetry established by M2 protocol was not statistically different from that calculated by M0; while M1 overestimates for all OARs but spleen.

Published
2022
Full Text
View/download PDF

11. Analysis of Pros and Cons in using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007: production, costs and PET/CT applications in patients with Prostate Cancer

Author

Maisto Costantina, Aurilio Michela, Morisco Anna, de Marino Roberta, Buonanno Recchimuzzo Monica Josefa, Carideo Luciano, D'Ambrosio Laura, Di Gennaro Francesca, Esposito Aureliana, Gaballo Paolo, Pirozzi Palmese Valentina, Porfidia Valentina, Raddi Marco, Rossi Alfredo, Squame Elisabetta, and Lastoria Secondo

Subjects
PCa, [68Ga]Ga-PSMA-11, [18F]PSMA-1007, PSMA, [68Ge]/[68Ga] generator, RCY, RCP
Abstract

The aim of this work is to compare [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 to highlight advantages and drawbacks, analyzing processes of synthesis, imaging properties related to the different pharmacokinetics features, and the consequent impact on patient eligibility for radioligand therapy (RLT). At least, economical aspects were also evaluated. For the production of [68Ga]Ga-PSMA-11, two ranges of starting activity of [68Ga]Gallium chloride and their impact on final radiochemical yeld (RCY), were considered: for the lower (X), with an average activity value of 596.55±37.97 MBq, the RCY was of 80.98±0.051 %, while for the higher range (Y), with an average starting activity value of1436.27±68.68 MBq, the RCY was 71.48±0.038 %. This demonstrated that the increasing starting activity of [68Ga]Gallium chloride negatively affects the RCY. Furthermore, economical evaluations suggested better advantages of [18F]PSMA-1007 vs [68Ga]Ga-PSMA-11..From our clinical experience, comparing all diagnostic and therapeutic PSMA-inhibitors used,there are no significant differences in their binding within tumor lesions but a different uptake in normal organs. Data resulting from this study allow us to search a new and promising approach to overcome the limitations observed in the routinary clinical activity for [68Ga]Ga-PSMA-11.

Published
2022
Full Text
View/download PDF

12. A Systematic Review on Combined [ 18 F]FDG and 68 Ga-SSA PET/CT in Pulmonary Carcinoid.

Author

Prosperi, Daniela, Carideo, Luciano, Russo, Vincenzo Marcello, Meucci, Rosaria, Campagna, Giuseppe, Lastoria, Secondo, and Signore, Alberto

Subjects
CARCINOID, NEUROENDOCRINE tumors, POSITRON emission tomography, SCINTILLATION cameras, COMPUTED tomography
Abstract

Pulmonary carcinoids (PCs) are part of a spectrum of well-differentiated neuroendocrine neoplasms (NENs) and are classified as typical carcinoid (TC) and atypical carcinoid (AC). TC differ from AC not only for its histopathological features but also for its "functional imaging pattern" and prognosis. ACs are more undifferentiated and characterized by higher aggressiveness. Positron emission tomography/computed tomography (PET/CT) with somatostatin analogs (SSA) labeled with Gallium-68 (68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE) has widely replaced conventional imaging with gamma camera using 111In- or 99mTc-labelled compounds and represents now the gold standard for diagnosis and management of NENs. In this setting, as already described for gastro-entero-pancreatic NENs, 18F-Fluorodeoxiglucose ([18F]FDG) in addition to 68Ga-SSA can play an important role in clinical practice, particularly for ACs that show a more aggressive behavior compared to TCs. The aim of this systematic review is to analyze all original studies collected from the PubMed and Scopus databases regarding PCs in which both 68Ga-SSA PET/CT and [18F]FDG PET/CT were performed in order to evaluate the clinical impact of each imaging modality. The following keywords were used for the research: "18F, 68Ga and (bronchial carcinoid or carcinoid lung)". A total of 57 papers were found, of which 17 were duplicates, 8 were reviews, 10 were case reports, and 1 was an editorial. Of the remaining 21 papers, 12 were ineligible because they did not focus on PC or did not compare 68Ga-SSA and [18F]FDG. We finally retrieved and analyzed nine papers (245 patients with TCs and 110 patients with ACs), and the results highlight the importance of the combined use of 68Ga-SSA and [18F]FDG PET/CT for the correct management of these neoplasms. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Analysis of Pros and Cons in Using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer

Author

Maisto, Costantina, primary, Aurilio, Michela, additional, Morisco, Anna, additional, de Marino, Roberta, additional, Buonanno Recchimuzzo, Monica Josefa, additional, Carideo, Luciano, additional, D’Ambrosio, Laura, additional, Di Gennaro, Francesca, additional, Esposito, Aureliana, additional, Gaballo, Paolo, additional, Pirozzi Palmese, Valentina, additional, Porfidia, Valentina, additional, Raddi, Marco, additional, Rossi, Alfredo, additional, Squame, Elisabetta, additional, and Lastoria, Secondo, additional

Published
2022
Full Text
View/download PDF

15. Additional file 1 of Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization

Author

Mallardo, Domenico, Simeone, Ester, Vanella, Vito, Vitale, Maria Grazia, Palla, Marco, Scarpato, Luigi, Paone, Miriam, De Cristofaro, Teresa, Borzillo, Valentina, Cortellini, Alessio, Sparano, Francesca, Pignata, Sandro, Fiore, Francesco, Caracò, Corrado, Maiolino, Piera, Petrillo, Antonella, Cavalcanti, Ernesta, Lastoria, Secondo, Muto, Paolo, Budillon, Alfredo, Warren, Sarah, and Ascierto, Paolo Antonio

Abstract

Additional file 1. Supplementary table 1. Description of genes expressed either with cetirizine administration or without cetirizine in the overall population.

Published
2022
Full Text
View/download PDF

16. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors

Author

Pusceddu, Sara, primary, Prinzi, Natalie, additional, Tafuto, Salvatore, additional, Ibrahim, Toni, additional, Filice, Angelina, additional, Brizzi, Maria Pia, additional, Panzuto, Francesco, additional, Baldari, Sergio, additional, Grana, Chiara M., additional, Campana, Davide, additional, Davì, Maria Vittoria, additional, Giuffrida, Dario, additional, Zatelli, Maria Chiara, additional, Partelli, Stefano, additional, Razzore, Paola, additional, Marconcini, Riccardo, additional, Massironi, Sara, additional, Gelsomino, Fabio, additional, Faggiano, Antongiulio, additional, Giannetta, Elisa, additional, Bajetta, Emilio, additional, Grimaldi, Franco, additional, Cives, Mauro, additional, Cirillo, Fernando, additional, Perfetti, Vittorio, additional, Corti, Francesca, additional, Ricci, Claudio, additional, Giacomelli, Luca, additional, Porcu, Luca, additional, Di Maio, Massimo, additional, Seregni, Ettore, additional, Maccauro, Marco, additional, Lastoria, Secondo, additional, Bongiovanni, Alberto, additional, Versari, Annibale, additional, Persano, Irene, additional, Rinzivillo, Maria, additional, Pignata, Salvatore Antonio, additional, Rocca, Paola Anna, additional, Lamberti, Giuseppe, additional, Cingarlini, Sara, additional, Puliafito, Ivana, additional, Ambrosio, Maria Rosaria, additional, Zanata, Isabella, additional, Bracigliano, Alessandra, additional, Severi, Stefano, additional, Spada, Francesca, additional, Andreasi, Valentina, additional, Modica, Roberta, additional, Scalorbi, Federica, additional, Milione, Massimo, additional, Sabella, Giovanna, additional, Coppa, Jorgelina, additional, Casadei, Riccardo, additional, Di Bartolomeo, Maria, additional, Falconi, Massimo, additional, and de Braud, Filippo, additional

Published
2022
Full Text
View/download PDF

17. Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion

Author

Morabito, Alessandro, primary, Manzo, Anna, additional, Montanino, Agnese, additional, Rachiglio, Anna Maria, additional, Sforza, Vincenzo, additional, Pasquale, Raffaella, additional, Costanzo, Raffaele, additional, Maiello, Monica R, additional, Sandomenico, Claudia, additional, Gallo, Marianna, additional, Palumbo, Giuliano, additional, De Luca, Antonella, additional, La Rocca, Antonello, additional, Martucci, Nicola, additional, De Cecio, Rossella, additional, Picone, Carmine, additional, Lastoria, Secondo, additional, and Normanno, Nicola, additional

Published
2022
Full Text
View/download PDF

18. Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer

Author

Avallone, Antonio, Piccirillo, Maria C., Nasti, Guglielmo, Rosati, Gerardo, Carlomagno, Chiara, Di Gennaro, Elena, Romano, Carmela, Tatangelo, Fabiana, Granata, Vincenza, Cassata, Antonino, Silvestro, Lucrezia, De Stefano, Alfonso, Aloj, Luigi, Vicario, Valeria, Nappi, Anna, Leone, Alessandra, Bilancia, Domenico, Arenare, Laura, Petrillo, Antonella, Lastoria, Secondo, Gallo, Ciro, Botti, Gerardo, Delrio, Paolo, Izzo, Francesco, Perrone, Franco, and Budillon, Alfredo

Subjects
Adult, Diarrhea, Male, genetic structures, Adolescent, Drug-Related Side Effects and Adverse Reactions, Research, Angiogenesis Inhibitors, Nausea, Middle Aged, Progression-Free Survival, Bevacizumab, Oxaliplatin, Online Only, Young Adult, Treatment Outcome, Oncology, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Humans, Female, Neoplasm Metastasis, Colorectal Neoplasms, Original Investigation, Aged
Abstract

Key Points Question Does sequential scheduling of bevacizumab administration in combination with chemotherapy improve treatment efficacy in patients with metastatic colorectal cancer in keeping with the tumor vascular normalization hypothesis? Findings In this phase 3 randomized clinical trial of 230 patients, the primary end point objective response rate did not significantly differ between the sequential and the concomitant schedule of bevacizumab administration in combination with standard oxaliplatin-based regimens. However, the sequential schedule of bevacizumab administration was associated with longer overall survival, fewer adverse effects, and better health-related quality of life. Meaning Sequential bevacizumab scheduling plus chemotherapy might be relevant to optimize therapeutic efficacy and to explore antiangiogenic combination treatments with innovative perspectives., This randomized clinical trial compares outcomes of concomitant and sequential administration of bevacizumab in combination with standard oxaliplatin-based regimens in untreated or single line–treated patients with metastatic colorectal cancer., Importance Although bevacizumab is a standard of care in combination treatments for metastatic colorectal cancer (mCRC), its clinical benefit has been limited. Objective To determine whether sequential scheduling of bevacizumab administration in combination with chemotherapy improves treatment efficacy in patients with mCRC, in keeping with the tumor vascular normalization hypothesis. Design, Setting, and Participants This open-label, randomized clinical phase 3 trial was conducted from May 8, 2012, to December 9, 2015, at 3 Italian centers. Patients aged 18 to 75 years with unresectable, previously untreated, or single line–treated mCRC were recruited. Follow-up was completed December 31, 2019, and data were analyzed from February 26 to July 24, 2020. Interventions Patients received 12 biweekly cycles of standard oxaliplatin-based regimens (modified FOLFOX-6 [levo–folinic acid, fluorouracil, and oxaliplatin]/modified CAPOX [capecitabine and oxaliplatin]) plus bevacizumab administered either on the same day as chemotherapy (standard arm) or 4 days before chemotherapy (experimental arm). Main Outcomes and Measures The primary end point was the objective response rate (ORR) measured with Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary end points included progression-free survival, overall survival, safety, and quality of life (QOL). Results Overall, 230 patients (136 men [59.1%]; median age, 62.3 [interquartile range, 53.3-67.6] years) were randomly assigned to the standard arm (n = 115) or the experimental arm (n = 115). The median duration of follow-up was 68.3 (95% CI, 61.0-70.0) months. No difference in ORR (57.4% [95% CI, 47.8%-66.6%] in the standard arm and 56.5% [95% CI, 47.0-65.7] in the experimental arm; P = .89) or progression-free survival (10.5 [95% CI, 9.1-12.3] months in the standard arm and 11.7 [95% CI, 9.9-12.9] months in the experimental arm; P = .15) was observed. However, the median overall survival was 29.8 (95% CI, 22.5-41.1) months in the experimental arm compared with 24.1 (95% CI, 18.6-29.8) months in the standard arm (adjusted hazard ratio, 0.73; 95% CI, 0.54-0.99; P = .04). Moreover, the experimental arm was associated with a significant reduction in the rate of severe diarrhea (6 [5.3%] vs 19 [16.5%]; P = .006) and nausea (2 [1.8%] vs 8 [7.0%]; P = .05) and improved physical functioning (mean [SD] change from baseline, 0.65 [1.96] vs −7.41 [2.95] at 24 weeks; P = .02), and constipation scores (mean [SD] change from baseline, −17.2 [3.73] vs −0.62 [4.44]; P = .003). Conclusions and Relevance In this randomized clinical trial, sequential administration of bevacizumab plus chemotherapy did not improve ORR, the primary end point. However, the overall survival advantage, fewer adverse effects, and better health-related QOL associated with sequential bevacizumab administration might provide the basis for exploring antiangiogenic combination treatments with innovative perspectives. Trial Registration EudraCT Identifier: 2011-004997-27; ClinicalTrials.gov Identifier: NCT01718873

Published
2021

19. A Multicenter Randomized Controlled Prospective Study to Assess Efficacy of Laparoscopic Electrochemotherapy in the Treatment of Locally Advanced Pancreatic Cancer

Author

Izzo, Francesco, primary, Granata, Vincenza, additional, Fusco, Roberta, additional, D’Alessio, Valeria, additional, Petrillo, Antonella, additional, Lastoria, Secondo, additional, Piccirillo, Mauro, additional, Albino, Vittorio, additional, Belli, Andrea, additional, Nasti, Guglielmo, additional, Avallone, Antonio, additional, Patrone, Renato, additional, Grassi, Francesca, additional, Leongito, Maddalena, additional, and Palaia, Raffaele, additional

Published
2021
Full Text
View/download PDF

20. Oligometastatic prostate cancer treatment

Author

Rossetti, Sabrina, primary, Di Napoli, Marilena, additional, Pisano, Carmela, additional, C Cecere, Sabrina, additional, Tambaro, Rosa, additional, Ventriglia, Jole, additional, Passarelli, Anna, additional, Iovane, Gelsomina, additional, Feroce, Florinda, additional, Lastoria, Secondo, additional, Di Gennaro, Francesca, additional, Muto, Paolo, additional, Borzillo, Valentina, additional, Di Franco, Rossella, additional, Perdonà, Sisto, additional, Quarto, Giuseppe, additional, and Pignata, Sandro, additional

Published
2021
Full Text
View/download PDF

21. Clinical Phase I/II Study: Local Disease Control and Survival in Locally Advanced Pancreatic Cancer Treated with Electrochemotherapy

Author

Izzo, Francesco, primary, Granata, Vincenza, additional, Fusco, Roberta, additional, D'Alessio, Valeria, additional, Petrillo, Antonella, additional, Lastoria, Secondo, additional, Piccirillo, Mauro, additional, Albino, Vittorio, additional, Belli, Andrea, additional, Tafuto, Salvatore, additional, Avallone, Antonio, additional, Patrone, Renato, additional, and Palaia, Raffaele, additional

Published
2021
Full Text
View/download PDF

22. Correction: Ionna et al. Sentinel Lymph Node Biopsy (SLNB) for Early-Stage Head and Neck Squamous-Cell Carcinoma of the Tongue: Twenty Years of Experience at I.N.T. "G.Pascale". Cancers 2024, 16 , 1153.

Author

Ionna, Franco, Pavone, Ettore, Aversa, Corrado, Maffia, Francesco, Spinelli, Raffaele, Carraturo, Emanuele, Salzano, Giovanni, Maglitto, Fabio, Sarcinella, Marco, Fusco, Roberta, Granata, Vincenza, Lastoria, Secondo, Prato, Francesco Del, and Maglione, Maria Grazia

Subjects
SENTINEL lymph node biopsy, HEAD & neck cancer, QUALITY of life, TUMOR classification, TONGUE tumors, EPITHELIAL cell tumors
Published
2024
Full Text
View/download PDF

23. Analysis of Pros and Cons in Using [ 68 Ga]Ga-PSMA-11 and [ 18 F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer.

Author

Maisto, Costantina, Aurilio, Michela, Morisco, Anna, de Marino, Roberta, Buonanno Recchimuzzo, Monica Josefa, Carideo, Luciano, D'Ambrosio, Laura, Di Gennaro, Francesca, Esposito, Aureliana, Gaballo, Paolo, Pirozzi Palmese, Valentina, Porfidia, Valentina, Raddi, Marco, Rossi, Alfredo, Squame, Elisabetta, and Lastoria, Secondo

Subjects
PROSTATE cancer patients, POSITRON emission tomography, COMPUTED tomography
Abstract

The aim of this work is to compare [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT as imaging agents in patients with prostate cancer (PCa). Comparisons were made by evaluating times and costs of the radiolabeling process, imaging features including pharmacokinetics, and impact on patient management. The analysis of advantages and drawbacks of both radioligands might help to make a better choice based on firm data. For [68Ga]Ga-PSMA-11, the radiochemical yield (RCY) using a low starting activity (L, average activity of 596.55 ± 37.97 MBq) was of 80.98 ± 0.05%, while using a high one (H, average activity of 1436.27 ± 68.68 MBq), the RCY was 71.48 ± 0.04%. Thus, increased starting activities of [68Ga]-chloride negatively influenced the RCY. A similar scenario occurred for [18F]PSMA-1007. The rate of detection of PCa lesions by Positron Emission Tomography/Computed Tomography (PET/CT) was similar for both radioligands, while their distribution in normal organs significantly differed. Furthermore, similar patterns of biodistribution were found among [18F]PSMA-1007, [68Ga]Ga-PSMA-11, and [177Lu]Lu-PSMA-617, the most used agent for RLT. Moreover, the analysis of economical aspects for each single batch of production corrected for the number of allowed PET/CT examinations suggested major advantages of [18F]PSMA-1007 compared with [68Ga]Ga-PSMA-11. Data from this study should support the proper choice in the selection of the PSMA PET radioligand to use on the basis of the cases to study. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

25. On site production of [18F]PSMA-1007 using different [18F]fluoride activities: practical, technical and economical impact.

Author

Maisto, Costantina, Morisco, Anna, de Marino, Roberta, Squame, Elisabetta, Porfidia, Valentina, D'Ambrosio, Laura, Di Martino, Daria, Gaballo, Paolo, Aurilio, Michela, Buonanno, Monica, Esposito, Aureliana, Raddi, Marco, and Lastoria, Secondo

Subjects
COMPUTED tomography, RADIOCHEMICAL purification, POSITRON emission tomography, PROSTATE
Abstract

Background: Prostate-specific membrane antigen is overexpressed in prostate cancer and it is considered a good target for positron emission tomography/computed tomography imaging of primary cancer and recurrent/metastatic disease, as well as for radioligand therapy. Different PSMA-analogues labeled with [68Ga]gallium have been investigated, showing excellent imaging properties; however, only small amounts can be produced for each radiolabeling. Recently, a [18F]fluoride labeled PSMA-inhibitor, [18F]PSMA-1007, has been introduced, and it has ensured large-scale productions, overcoming this limitation of [68Ga]PSMAs. In this study, PSMA-1007 has been labeled with low (A), medium (B) and high (C) starting activities of [18F]fluoride, in order to verify if radiochemical yield, radiochemical purity and stability of [18F]PSMA-1007 were affected. These parameters have been measured in sixty-five consecutive batches. In addition, the estimation of [18F]PSMA-1007 production costs is provided. Results: The radiochemical yield for low and medium activities of [18F]fluoride was 52%, while for the high one it decreased to 40%. The radiochemical purity was 99% for all three activities. [18F]PSMA-1007 did not show radiolysis up to 8 h after the end of synthesis, confirming that the radiopharmaceutical is stable and suitable to perform diagnostic studies in humans for a long period of time after the end of radiolabeling. Furthermore, radiochemical stability was demonstrated in fetal bovine serum at 4 °C and 37 °C for 120′. Conclusions: A starting activity of [18F]fluoride of 90 GBq (B) seems to be the best option enabling a final amount of about of 50 GBq of [18F]PSMA-1007, which is promising as it allows to: (a) perform a large number of scans, and/or (b) supply the radiopharmaceutical to any peripheral diagnostic centers in need. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

29. Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report

Author

Simeone Ester, De Maio Eleonora, Sandomenico Fabio, Fulciniti Franco, Lastoria Secondo, Aprea Pasquale, Staibano Stefania, Montesarchio Vincenzo, Palmieri Giuseppe, Mozzillo Nicola, and Ascierto Paolo A

Subjects
Medicine
Abstract

Abstract Introduction Leptomeningeal metastases are occurring at higher frequency in cancer patients. The prognosis of leptomeningeal metastases is poor and standard treatment, which includes radiotherapy and chemotherapy, is mostly ineffective. Melanoma represents one of the tumors with the highest incidence of leptomeningeal metastases. For such a disease, the BRAF inhibitors have recently been demonstrated to be effective on melanoma brain metastases harboring the V600EBRAF mutation. Case presentation We report a case of a 39-year-old Italian woman with advanced melanoma with brain, lung and peritoneum metastases harboring the V600EBRAF mutation. In August 2010 she was enrolled into the BRIM3 trial and after the randomization process she received dacarbazine. After two cycles, there was evidence of disease progression in her peritoneum and lung. For this reason, she was enrolled into another clinical trial with the GSK2118436 BRAF inhibitor, dabrafenib, as a second line of therapy. She had a partial response that was maintained until 13 weeks of treatment. In January 2011 she developed symptoms typical for brain metastases and received a diagnosis of leptomeningeal involvement of melanoma cells after an examination of her cerebral spinal fluid; magnetic resonance imaging was negative for meningitis or brain metastases. Analysis of her cerebral spinal fluid sample confirmed that the melanoma cells still carried the V600EBRAF mutation. After a few days, our patient went into a coma and died. Conclusion Starting with a clinical case, we discuss the pathogenesis of leptomeningeal metastases and whether the leptomeninges may represent a sanctuary where melanoma cells may generate resistance and/or BRAF inhibitors cannot reach an adequate concentration for significant activity. We assess whether treatment with BRAF inhibitors in melanoma patients should be interrupted as soon as disease progression appears or continued beyond progression, through the administration of additional compounds.

Published
2012
Full Text
View/download PDF

30. 18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer

Author

Avallone, Antonio, primary, Aloj, Luigi, additional, Pecori, Biagio, additional, Caracò, Corradina, additional, De Stefano, Alfonso, additional, Tatangelo, Fabiana, additional, Silvestro, Lucrezia, additional, Granata, Vincenza, additional, Bianco, Francesco, additional, Romano, Carmela, additional, Di Gennaro, Francesca, additional, Budillon, Alfredo, additional, Petrillo, Antonella, additional, Muto, Paolo, additional, Botti, Gerardo, additional, Delrio, Paolo, additional, and Lastoria, Secondo, additional

Published
2019
Full Text
View/download PDF

31. Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology

Author

Pascarella, Giacomo, primary, Capasso, Arturo, additional, Nardone, Antonio, additional, Triassi, Maria, additional, Pignata, Sandro, additional, Arenare, Laura, additional, Ascierto, Paolo, additional, Curvietto, Marcello, additional, Maiolino, Piera, additional, D’Aniello, Roberta, additional, Montanino, Agnese, additional, Laudato, Francesca, additional, De Feo, Gianfranco, additional, Botti, Gerardo, additional, Perrone, Francesco, additional, Petrillo, Antonella, additional, Cavalcanti, Ernesta, additional, Lastoria, Secondo, additional, Maurea, Nicola, additional, and Morabito, Alessandro, additional

Published
2019
Full Text
View/download PDF

32. Huge parathyroid carcinoma: Clinical considerations and literature review

Author

Marone Ugo, Lastoria Secondo, Losito Simona, Scognamiglio Francesco, Chiofalo Maria, and Pezzullo Luciano

Subjects
Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Parathyroid carcinoma is a rare malignancy, with an incidence of 0.5 to 4% of all cases of primary hyperparathyroidism. Surgery is the only curative treatment. Case presentation We report the case of a 66-year-old man referred for a large suspicious substernal goitre associated with severe hypercalcemia due to hyperparathyroidism. After normalization of serum calcium levels, patient underwent surgery. The voluminous cervicomediastinal firm mass could not be removed through the cervical incision; therefore a cervicothoracic approach was employed. Histopathology revealed a giant parathyroid cancer of 450 grams. A review of the literature was also undertaken to summarize the current treatment approaches for this rare malignancy. Conclusion Parathyroid cancer is usually not recognized either preoperatively or intra-operatively. En bloc resection of the tumour with the adjacent tissue is the treatment of choice and it is very important to avoid the rupture of the capsule during operation. Neither tumour size, nor the lymph node status appears to play a role in prognosis. The management of parathyroid carcinoma is a challenge even for experienced surgeons.

Published
2005
Full Text
View/download PDF

33. The treatment of hyperinsulinemic hypoglycaemia in adults: an update

Author

Davi′, M. V, Pia, A., Guarnotta, V., Pizza, G., Colao, A., Faggiano, A., On behalf of NIKE Group, Null, Albertelli, Manuela, Arvat, Emanuela, Baldelli, Roberto, Berruti, Alfredo, Bianchi, Antonio, Bodei, Lisa, Botti, Gerardo, Corcione, Francesco, Delle Fave, Gianfranco, De Marinis Grasso, Laura, De Rosa, Gaetano, Di Sarno, Antonella, Dicitore, Alessandra, Fazio, Nicola, Fanciulli, Giuseppe, Ferolla, Piero, Ferone, Diego, Filice, Angelina, Gallo, Marco, Giordano, Carla, Giuffrida, Dario, Lania, Andrea, Lastoria, Secondo, Logoluso, Francesco, Loli, Paola, Malandrino, Pasqualino, Manzoni, Marco, Marchetti, Massimo, Martini, Chiara, Messina, Erika, Modica, Roberta, Motta, Cecilia, Papotti, Mauro, Partelli, Stefano, Persico, Giovanni, Piovesan, Alessandro, Pontecorvi, Alfredo, Ramundo, Valeria, Razzore, Paola, Rota, Francesca, Scavuzzo, Francesco, Sciammarella, Concetta, Vitale, Giovanni, Chiara Zatelli, Maria, Davi, M. V, Pia, A, Guarnotta, V, Pizza, G, Colao, Annamaria, Faggiano, A., Davi, M., Pia, A., Guarnotta, V., Pizza, G., and Colao, A.

Subjects
Adult, medicine.medical_specialty, Pediatrics, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Gastric bypass, Nesidioblastosis, 030209 endocrinology & metabolism, Hypoglycemia, Settore MED/13 - Endocrinologia, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Hyperinsulinism, medicine, Hyperinsulinemic hypoglycaemia, Humans, Autoimmune hypoglycaemia, Insulinoma, Everolimus, business.industry, Treatment, Settore MED/13 - ENDOCRINOLOGIA, Nesidioblastosi, medicine.disease, Surgery, Diabetes and Metabolism, 030220 oncology & carcinogenesis, Differential diagnosis, business, hormones, hormone substitutes, and hormone antagonists, medicine.drug, Human
Abstract

Treatment of hyperinsulinemic hypoglycaemia (HH) is challenging due to the rarity of this condition and the difficulty of differential diagnosis. The aim of this article is to give an overview of the recent literature on the management of adult HH. A search for reviews, original articles, original case reports between 1995 and 2016 in PubMed using the following keywords: hyperinsulinemic hypoglycaemia, insulinoma, nesidioblastosis, gastric bypass, autoimmune hypoglycaemia, hyperinsulinism, treatment was performed. One hundred and forty articles were selected and analysed focusing on the most recent treatments of HH. New approaches to treatment of HH are available including mini-invasive surgical techniques and alternative local–regional ablative therapy for benign insulinoma and everolimus for malignant insulinoma. A correct differential diagnosis is of paramount importance to avoid unnecessary surgical operations and to implement the appropriate treatment mainly in the uncommon forms of HH, such as nesidioblastosis and autoimmune hypoglycaemia.

Published
2017

34. Correction: Sonoporation by microbubbles as gene therapy approach against liver cancer

Author

Rinaldi, Luca, primary, Folliero, Veronica, additional, Palomba, Luciana, additional, Zannella, Carla, additional, Isticato, Rachele, additional, Di Francia, Raffaele, additional, Berretta, Massimiliano, additional, de Sio, Ilario, additional, Adinolfi, Luigi E., additional, Morelli, Giancarlo, additional, Lastoria, Secondo, additional, Altucci, Lucia, additional, Pedone, Carlo, additional, Galdiero, Massimiliano, additional, and Franci, Gianluigi, additional

Published
2018
Full Text
View/download PDF

35. Sonoporation by microbubbles as gene therapy approach against liver cancer

Author

Rinaldi, Luca, primary, Folliero, Veronica, additional, Palomba, Luciana, additional, Zannella, Carla, additional, Isticato, Rachele, additional, Di Francia, Raffaele, additional, Berretta, Massimiliano, additional, de Sio, Ilario, additional, Adinolfi, Luigi E., additional, Morelli, Giancarlo, additional, Lastoria, Secondo, additional, Altucci, Lucia, additional, Pedone, Carlo, additional, Galdiero, Massimiliano, additional, and Franci, Gianluigi, additional

Published
2018
Full Text
View/download PDF

36. Sequential PET/CT with [18F]-FDG Predicts Pathological Tumor Response to Preoperative Short Course Radiotherapy with Delayed Surgery in Patients with Locally Advanced Rectal Cancer Using Logistic Regression Analysis

Author

Pecori, Biagio, primary, Lastoria, Secondo, additional, Caracò, Corradina, additional, Celentani, Marco, additional, Tatangelo, Fabiana, additional, Avallone, Antonio, additional, Rega, Daniela, additional, De Palma, Giampaolo, additional, Mormile, Maria, additional, Budillon, Alfredo, additional, Muto, Paolo, additional, Bianco, Francesco, additional, Aloj, Luigi, additional, Petrillo, Antonella, additional, and Delrio, Paolo, additional

Published
2017
Full Text
View/download PDF

38. 18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival to Preoperative Radiochemotherapy with Bevacizumab in High Risk Locally Advanced Rectal Cancer.

Author

Avallone, Antonio, Aloj, Luigi, Pecori, Biagio, Caracò, Corradina, De Stefano, Alfonso, Tatangelo, Fabiana, Silvestro, Lucrezia, Granata, Vincenza, Bianco, Francesco, Romano, Carmela, Di Gennaro, Francesca, Budillon, Alfredo, Petrillo, Antonella, Muto, Paolo, Botti, Gerardo, Delrio, Paolo, and Lastoria, Secondo

Published
2019
Full Text
View/download PDF

39. 18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer.

Author

Avallone, Antonio, Aloj, Luigi, Pecori, Biagio, Caracò, Corradina, De Stefano, Alfonso, Tatangelo, Fabiana, Silvestro, Lucrezia, Granata, Vincenza, Bianco, Francesco, Romano, Carmela, Di Gennaro, Francesca, Budillon, Alfredo, Petrillo, Antonella, Muto, Paolo, Botti, Gerardo, Delrio, Paolo, and Lastoria, Secondo

Published
2019
Full Text
View/download PDF

40. Standardized Index of Shape (DCE-MRI) and Standardized Uptake Value (PET/CT): Two quantitative approaches to discriminate chemo-radiotherapy locally advanced rectal cancer responders under a functional profile

Author

Petrillo, Antonella, primary, Fusco, Roberta, additional, Petrillo, Mario, additional, Granata, Vincenza, additional, Delrio, Paolo, additional, Bianco, Francesco, additional, Pecori, Biagio, additional, Botti, Gerardo, additional, Tatangelo, Fabiana, additional, Caracò, Corradina, additional, Aloj, Luigi, additional, Avallone, Antonio, additional, and Lastoria, Secondo, additional

Published
2016
Full Text
View/download PDF

41. 90Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Author

Lerch, Kristina, primary, Leng, Corinna, additional, Pinto, Antonello, additional, Linkesch, Werner, additional, Sill, Heinz, additional, Linden, Ola, additional, Viardot, Andreas, additional, Keller, Ulrich, additional, Hess, Georg, additional, Lastoria, Secondo, additional, Frigeri, Ferdinando, additional, Neik, Nicole, additional, Pott, Christiane, additional, Scholz, Christian W., additional, and Pezzutto, Antonio, additional

Published
2016
Full Text
View/download PDF

42. Induction of VX2 para-renal carcinoma in rabbits: generation of animal model for loco-regional treatments of solid tumors

Author

Bimonte, Sabrina, primary, Leongito, Maddalena, additional, Piccirillo, Mauro, additional, Tamma, Maria Luisa, additional, Vallifuoco, Marianna, additional, Bracco, Adele, additional, Mancini, Antonio, additional, Di Napoli, Daniele, additional, Castaldo, Sigismondo, additional, Cozzolino, Santolo, additional, Iacobellis, Francesca, additional, Grassi, Roberto, additional, Granata, Vincenza, additional, Lastoria, Secondo, additional, Curley, Steven, additional, and Izzo, Francesco, additional

Published
2016
Full Text
View/download PDF

43. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)

Author

Avallone, Antonio, primary, Piccirillo, Maria Carmela, additional, Aloj, Luigi, additional, Nasti, Guglielmo, additional, Delrio, Paolo, additional, Izzo, Francesco, additional, Di Gennaro, Elena, additional, Tatangelo, Fabiana, additional, Granata, Vincenza, additional, Cavalcanti, Ernesta, additional, Maiolino, Piera, additional, Bianco, Francesco, additional, Aprea, Pasquale, additional, De Bellis, Mario, additional, Pecori, Biagio, additional, Rosati, Gerardo, additional, Carlomagno, Chiara, additional, Bertolini, Alessandro, additional, Gallo, Ciro, additional, Romano, Carmela, additional, Leone, Alessandra, additional, Caracò, Corradina, additional, de Lutio di Castelguidone, Elisabetta, additional, Daniele, Gennaro, additional, Catalano, Orlando, additional, Botti, Gerardo, additional, Petrillo, Antonella, additional, Romano, Giovanni M., additional, Iaffaioli, Vincenzo R., additional, Lastoria, Secondo, additional, Perrone, Francesco, additional, and Budillon, Alfredo, additional

Published
2016
Full Text
View/download PDF

44. Hepatocellular carcinoma and liver metastases: clinical data on a new dual-lumen catheter kit for surgical sealant infusion to prevent perihepatic bleeding and dissemination of cancer cells following biopsy and loco-regional treatments

Author

Izzo, Francesco, primary, Palaia, Raffaele, additional, Albino, Vittorio, additional, Amore, Alfonso, additional, di Giacomo, Raimondo, additional, Piccirillo, Mauro, additional, Leongito, Maddalena, additional, Nasto, Aurelio, additional, Granata, Vincenza, additional, Petrillo, Antonella, additional, and Lastoria, Secondo, additional

Published
2015
Full Text
View/download PDF

45. Sequential PET/CT with [18F]-FDG Predicts Pathological Tumor Response to Preoperative Short Course Radiotherapy with Delayed Surgery in Patients with Locally Advanced Rectal Cancer Using Logistic Regression Analysis.

Author

Pecori, Biagio, Lastoria, Secondo, Caracò, Corradina, Celentani, Marco, Tatangelo, Fabiana, Avallone, Antonio, Rega, Daniela, De Palma, Giampaolo, Mormile, Maria, Budillon, Alfredo, Muto, Paolo, Bianco, Francesco, Aloj, Luigi, Petrillo, Antonella, and Delrio, Paolo

Subjects
*POSITRON emission tomography, *FLUORODEOXYGLUCOSE F18, *RECTAL cancer treatment, *CANCER radiotherapy, *ONCOLOGIC surgery, *PREOPERATIVE care, *LOGISTIC regression analysis
Abstract

Previous studies indicate that FDG PET/CT may predict pathological response in patients undergoing neoadjuvant chemo-radiotherapy for locally advanced rectal cancer (LARC). Aim of the current study is evaluate if pathological response can be similarly predicted in LARC patients after short course radiation therapy alone. Methods: Thirty-three patients with cT2-3, N0-2, M0 rectal adenocarcinoma treated with hypo fractionated short course neoadjuvant RT (5x5 Gy) with delayed surgery (SCRTDS) were prospectively studied. All patients underwent 3 PET/CT studies at baseline, 10 days from RT end (early), and 53 days from RT end (delayed). Maximal standardized uptake value (SUVmax), mean standardized uptake value (SUVmean) and total lesion glycolysis (TLG) of the primary tumor were measured and recorded at each PET/CT study. We use logistic regression analysis to aggregate different measures of metabolic response to predict the pathological response in the course of SCRTDS. Results: We provide straightforward formulas to classify response and estimate the probability of being a major responder (TRG1-2) or a complete responder (TRG1) for each individual. The formulas are based on the level of TLG at the early PET and on the overall proportional reduction of TLG between baseline and delayed PET studies. Conclusions: This study demonstrates that in the course of SCRTDS it is possible to estimate the probabilities of pathological tumor responses on the basis of PET/CT with FDG. Our formulas make it possible to assess the risks associated to LARC borne by a patient in the course of SCRTDS. These risk assessments can be balanced against other health risks associated with further treatments and can therefore be used to make informed therapy adjustments during SCRTDS. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

46. Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial)

Author

Avallone, Antonio, primary, Piccirillo, Maria Carmela, additional, Delrio, Paolo, additional, Pecori, Biagio, additional, Di Gennaro, Elena, additional, Aloj, Luigi, additional, Tatangelo, Fabiana, additional, D’Angelo, Valentina, additional, Granata, Cinzia, additional, Cavalcanti, Ernesta, additional, Maurea, Nicola, additional, Maiolino, Piera, additional, Bianco, Franco, additional, Montano, Massimo, additional, Silvestro, Lucrezia, additional, Terranova Barberio, Manuela, additional, Roca, Maria Serena, additional, Di Maio, Massimo, additional, Marone, Pietro, additional, Botti, Gerardo, additional, Petrillo, Antonella, additional, Daniele, Gennaro, additional, Lastoria, Secondo, additional, Iaffaioli, Vincenzo R, additional, Romano, Giovanni, additional, Caracò, Corradina, additional, Muto, Paolo, additional, Gallo, Ciro, additional, Perrone, Francesco, additional, and Budillon, Alfredo, additional

Published
2014
Full Text
View/download PDF

48. Early PET/CT Scan Is More Effective Than RECIST in Predicting Outcome of Patients with Liver Metastases from Colorectal Cancer Treated with Preoperative Chemotherapy Plus Bevacizumab

Author

Lastoria, Secondo, primary, Piccirillo, Maria Carmela, additional, Caracò, Corradina, additional, Nasti, Guglielmo, additional, Aloj, Luigi, additional, Arrichiello, Cecilia, additional, de Lutio di Castelguidone, Elisabetta, additional, Tatangelo, Fabiana, additional, Ottaiano, Alessandro, additional, Iaffaioli, Rosario Vincenzo, additional, Izzo, Francesco, additional, Romano, Giovanni, additional, Giordano, Pasqualina, additional, Signoriello, Simona, additional, Gallo, Ciro, additional, and Perrone, Francesco, additional

Published
2013
Full Text
View/download PDF

49. Abstract 4695: Predictive role of FDG PET-CT in monitoring locally advanced rectal cancer (LARC) during preoperative radiochemotherapy with an experimental bevacizumab schedule.

Author

Avallone, Antonio, primary, Delrio, Paolo, additional, Pecori, Biagio, additional, Tatangelo, Fabiana, additional, Di Gennaro, Elena, additional, Petrillo, Antonella, additional, Iaffaioli, Vincenzo Rosario, additional, Leone, Alessandra, additional, caracò, Corradina, additional, Budillon, Alfredo, additional, Lastoria, Secondo, additional, and Aloj, Luigi, additional

Published
2013
Full Text
View/download PDF

50. Abstract 2672: Early evaluation of response to Vemurafenib treatment with FDG PET/CT in patients with metastatic melanoma.

Author

Aloj, Luigi, primary, Caracò, Corradina, additional, Di Gennaro, Francesca, additional, Grimaldi, Antonio M., additional, Simeone, Ester, additional, Curvietto, Marcello, additional, Caracò, Corrado, additional, Mozzillo, Nicola, additional, Torri, Valter, additional, Ascierto, Paolo A., additional, and Lastoria, Secondo, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results